Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b 850,"Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89",joint integrity trait,,RS:0000239,DA/Bkl,both,126 days to 66 days,105,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,variable,immunized,10,days,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,69959,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 850,"Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89",joint integrity trait,,RS:0000154,BN/SsN,both,126 days to 66 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,variable,immunized,10,days,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,69961,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003684,LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru,both,0 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,15.4,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70193,Freund's incomplete adjuvant (200 ul) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,female,0 days,8,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69624,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,male,0 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69625,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,female,0 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,73,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69626,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,male,0 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,85,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69627,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,female,0 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,14,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69628,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,male,0 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,11,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69629,squalene (860 mg/ml) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69716,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,18,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69717,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,16,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,69,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69718,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69719,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69720,squalene (200 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69721,squalene (200 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69722,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69723,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69724,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,90,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69725,pristane (150 ul) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000495,LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc,female,0 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,29,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69642,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000495,LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc,male,0 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69643,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000496,LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc,female,0 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,77,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69644,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000496,LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc,male,0 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,71,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69645,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000492,LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc,female,0 days,26,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,69,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69646,squalene (860 mg/ml) , 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000492,LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc,male,0 days,28,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69647,squalene (860 mg/ml) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000513,LEW/Han,both,98 days to 56 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,82,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69660,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000497,LEW.1F,both,98 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69661,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0002062,LEW.1N,both,98 days to 56 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,64,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69662,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,98 days to 56 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69663,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,98 days to 56 days,23,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,9,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69664,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000382,DXE1/Ztm,both,98 days to 56 days,20,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,70,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69665,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69666,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69667,pristane (150 ul) , 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000382,DXE1/Ztm,both,98 days to 56 days,20,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69681,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69703,squalene (200 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69704,squalene (200 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,73,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69705,squalene (200 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,16,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,88,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69706,Freund's complete adjuvant (100 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69707,Freund's complete adjuvant (100 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,36,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69708,Freund's complete adjuvant (100 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69709,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69710,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,71,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69711,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69712,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),both,200 days to 120 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69713,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,male,200 days to 120 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69714,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),male,200 days to 120 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69715,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000497,LEW.1F,male,84 days to 56 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,86,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69813,pristane (150 ul) , 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000497,LEW.1F,female,84 days to 56 days,8,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69814,pristane (150 ul) , 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000202,E3,male,84 days to 56 days,5,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69815,pristane (150 ul) , 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000202,E3,female,84 days to 56 days,5,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69816,pristane (150 ul) , 1164,"Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,84 days to 56 days,104,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,2419200.0,,,,,pristane (150 ul) ,69838,pristane (150 ul) , 1164,"Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16.",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,84 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,2419200.0,,,,,pristane (150 ul) ,69839,pristane (150 ul) , 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,234 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70128,pristane (150 ul) , 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000497,LEW.1F,both,234 days to 56 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70129,pristane (150 ul) , 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000202,E3,both,234 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70130,pristane (150 ul) , 1298,"Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32.",joint integrity trait,,RS:0000384,DXE3/Ztm,both,0 days,29,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,3,%,,,MMO:0000163,in vivo visual assessment,,9504000.0,,,,,pristane (150 ul) (for 110 days),70142,pristane (150 ul) (for 110 days), 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000239,DA/Bkl,male,126 days to 63 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70146,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000239,DA/Bkl,female,126 days to 63 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70147,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000363,F344/NHsd,male,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,20,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70148,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000363,F344/NHsd,female,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70149,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000209,DA.F344-(D10Arb20-D10Arb22)/Arb,male,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70152,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000209,DA.F344-(D10Arb20-D10Arb22)/Arb,female,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70153,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0001225,DA.F344-(D10Rat204-D10Arb22)/Arb,male,126 days to 63 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70154,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0001225,DA.F344-(D10Rat204-D10Arb22)/Arb,female,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70155,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,0 days,30,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,93,%,,,MMO:0000163,in vivo visual assessment,,4838400.0,,,,,pristane (150 ul) (for 56 days),69591,pristane (150 ul) (for 56 days), 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,0 days,25,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,4838400.0,,,,,pristane (150 ul) (for 56 days),69592,pristane (150 ul) (for 56 days), 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,25,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70197,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),both,0 days,7,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70199,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,0 days,37,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,5,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70201,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,27,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,96.3,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70188,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002061,LEW.1AV1/Kini,both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70189,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002085,PVG.1AV1/Kini,both,0 days,29,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70190,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000225,DA.PVG-(D4Rat141-D4Mgh11),both,0 days,30,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70191,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,5,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70192,Freund's incomplete adjuvant (200 ul) , 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,69551,Freund's incomplete adjuvant (0.1 ml) , 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,83.3,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,69552,Freund's incomplete adjuvant (0.1 ml) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003691,DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,45,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84878,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003692,DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru,both,0 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84879,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003687,PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru,both,0 days,16,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,68.8,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84872,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003683,DA.LEW.1AV1-(D4Mgh17-D4Mgh21)/Kiru,both,0 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84873,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,0 days,7,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84874,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003688,DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru,both,0 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84875,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003689,DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru,both,0 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,22,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84876,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003690,DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84877,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003693,DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru,both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84880,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003694,DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru,both,0 days,7,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,43,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84881,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003695,DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru,both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,75,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84882,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84883,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003370,DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru,both,0 days,8,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84884,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003524,DA.PVG.1AV1-(D4Got126-D4Got136),both,0 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,64,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84886,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003371,DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,55,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84889,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003696,DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru,both,0 days,18,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,89,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84892,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,male,0 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84465,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,91.7,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84466,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,93,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84469,Freund's incomplete adjuvant (200 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84470,Freund's incomplete adjuvant (200 ul) , 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000531,LEW/SsNHsd,not specified,105 days to 77 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,97068,Freund's incomplete adjuvant (0.1 ml) , 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000531,LEW/SsNHsd,not specified,105 days to 77 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,0.9% sodium chloride solution (0.1 ml) ,97069,0.9% sodium chloride solution (0.1 ml) , 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,0.9% sodium chloride solution (0.1 ml) ,97070,0.9% sodium chloride solution (0.1 ml) , 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,0.9% sodium chloride solution (0.1 ml) ,97071,0.9% sodium chloride solution (0.1 ml) ,